GlassScriptPhysician profile
Nirmala Saraf
NPI 1518986538
$11,128.26
in general payments reported to CMS, 2019-2025
47 companies · $878 in 2025
The $878 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,450 · 2020: $1,105 · 2021: $1,617 · 2022: $2,035 · 2023: $1,664 · 2024: $1,378 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,886 · Education: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,886.35 |
| Education | $1,033.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,292.84 | 2019-2025 | Jakafi |
| Janssen Biotech, INC. | $1,170.11 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $1,169.55 | 2019-2025 | Lynparza, Enhertu, Farxiga |
| Amgen INC. | $694.89 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Seagen INC. | $694.17 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $667.93 | 2019-2024 | Keytruda, Lynparza |
| Astellas Pharma US INC | $614.49 | 2019-2024 | Padcev, Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $566.57 | 2019-2025 | |
| Pfizer INC. | $563.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $453.17 | 2019-2023 | Reblozyl |
| Celgene Corporation | $341.03 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $317.54 | 2019-2025 | Ninlaro, Iclusig |
| Eisai INC. | $294.19 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $282.17 | 2019-2025 | |
| Genentech USA, INC. | $199.90 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirmala Saraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.